'Should have thought about debt but...' Pharmeasy CEO Siddharth Shah opens up about Thyrocare acquisition

Pharmeasy CEO Defends Thyrocare Acquisition, Acknowledges Oversight, and Emphasizes Commitment to Sustainable Growth and Shareholder Value

Expert Analysis:

• Strategic Defense:

  • Pharmeasy CEO justifies Thyrocare acquisition for strategic fit and digital growth potential.

• Learning from Oversight:

  • Acknowledge oversight on debt, and I want you to know that I'm committed to learning from my mistakes.

• Shareholder Dedication:

  • Rights Issue, with Rs 132 crore employee investment, underscores dedication to shareholder benefits.

• Sustainable Growth Focus:

  • Focus on sustainable growth aligns with evolving market dynamics.

• Repeat Customer Leverage:

  • With 77% revenue from repeat customers, it expects improved operating leverage for Pharmeasy.